These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31805583)

  • 41. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?
    Moreno-Cubero E; Del Arco RTS; Peña-Asensio J; de Villalobos ES; Míquel J; Larrubia JR
    World J Gastroenterol; 2018 May; 24(17):1825-1838. PubMed ID: 29740199
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies.
    Degasperi E; Anolli MP; Lampertico P
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366502
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B.
    Fung J; Lai CL; Yuen MF
    Expert Rev Anti Infect Ther; 2010 Jun; 8(6):717-26. PubMed ID: 20521898
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
    Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
    J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy.
    Li J; Sun X; Fang J; Wang C; Han G; Ren W
    Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):635-643. PubMed ID: 28438570
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatitis B Virus Cure: Targets and Future Therapies.
    Lee HW; Lee JS; Ahn SH
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379331
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of HBsAg quantification for monitoring natural history and treatment outcome.
    Martinot-Peignoux M; Lapalus M; Asselah T; Marcellin P
    Liver Int; 2013 Feb; 33 Suppl 1():125-32. PubMed ID: 23286856
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of hepatitis B virus (HBV) surface-gene variability on markers of replication during treated human immunodeficiency virus-HBV infection in Western Africa.
    Boyd A; Moh R; Maylin S; Abdou Chekaraou M; Mahjoub N; Gabillard D; Anglaret X; Eholié SP; Danel C; Delaugerre C; Zoulim F; Lacombe K;
    Liver Int; 2019 Feb; 39(2):280-289. PubMed ID: 30257068
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
    Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
    J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus.
    Kim SW; Yoon JS; Lee M; Cho Y
    Clin Mol Hepatol; 2022 Jan; 28(1):17-30. PubMed ID: 34281294
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HBV cure: why, how, when?
    Levrero M; Testoni B; Zoulim F
    Curr Opin Virol; 2016 Jun; 18():135-43. PubMed ID: 27447092
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers.
    Pfefferkorn M; Böhm S; Schott T; Deichsel D; Bremer CM; Schröder K; Gerlich WH; Glebe D; Berg T; van Bömmel F
    Gut; 2018 Nov; 67(11):2045-2053. PubMed ID: 28951526
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The difficulties of managing severe hepatitis B virus reactivation.
    Roche B; Samuel D
    Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?
    Vlachogiannakos J; Papatheodoridis GV
    Liver Int; 2014 Feb; 34 Suppl 1():127-32. PubMed ID: 24373089
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
    Lampertico P; Viganò M; Colombo M
    Liver Int; 2013 Feb; 33 Suppl 1():157-63. PubMed ID: 23286860
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Application of the new serum markers in the research and development of innovative hepatitis B drugs].
    Lu FM; Wang J; Chen XM; Zhang XX; Zhang WH; Xu XY; Jia JD; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):649-653. PubMed ID: 32911901
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment.
    Hao R; Xiang K; Peng Y; Hou J; Sun J; Li Y; Su M; Yan L; Zhuang H; Li T
    Infect Genet Evol; 2015 Jul; 33():261-8. PubMed ID: 25976382
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-Term Follow-up and Quantitative Hepatitis B Surface Antigen Monitoring in North American Chronic HBV Carriers.
    O'Neil CR; Congly SE; Rose MS; Lee SS; Borman MA; Charlton CL; Osiowy C; Swain MG; Burak KW; Coffin CS
    Ann Hepatol; 2018; 17(2):232-241. PubMed ID: 31097238
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
    Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
    J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.